|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:alsoKnownAs
|
umifenovir
|
|
gptkbp:approvedBy
|
gptkb:China
gptkb:Russia
|
|
gptkbp:ATCCode
|
J05AX13
|
|
gptkbp:CASNumber
|
131707-23-8
|
|
gptkbp:category
|
antiviral drug
broad-spectrum antiviral
fusion inhibitor
|
|
gptkbp:chemicalFormula
|
C22H25BrN2O3S
|
|
gptkbp:compatibleWith
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Russia
|
|
gptkbp:discoveredBy
|
gptkb:Russian_Academy_of_Medical_Sciences
|
|
gptkbp:discoveredIn
|
1970s
|
|
gptkbp:effectivenessForCOVID19
|
unknown
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Arbidol
|
|
gptkbp:legalStatus
|
prescription only (in Russia and China)
|
|
gptkbp:marketedAs
|
gptkb:Pharmstandard
|
|
gptkbp:mechanismOfAction
|
inhibits membrane fusion of the viral envelope
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
allergic reactions
gastrointestinal disturbances
|
|
gptkbp:studiedBy
|
gptkb:COVID-19
|
|
gptkbp:usedFor
|
treatment of influenza
treatment of respiratory viral infections
|
|
gptkbp:WHOStatus
|
not recommended by WHO for COVID-19
|
|
gptkbp:bfsParent
|
gptkb:Pharmstandard
|
|
gptkbp:bfsLayer
|
8
|